Phase II/II study of Adriamycin and Cisplatin versus Adriamycin for TC or DC resistant endometrial cancer

Phase II/II study of Adriamycin and Cisplatin versus Adriamycin for TC or DC resistant endometrial cancer - Phase II/II study of Adriamycin and Cisplatin versus Adriamycin for TC or DC resistant endometrial cancer

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009459

Enrollment

Registered

2013-01-01

Start date

2013-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

recurrent endometrial cancer

Interventions

AP therapy (Adriamycin 60mg/m2, cisplatin 50mg/m2 day1 q 3weeks) 20cases, registration period is from 01/01/2013 - 12/31/2015, follow up period is until 12/31/-2018 A therapy (Adriamycin 60mg/m2 day

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: paclitaxel/carboplatin or docetaxel/carboplatin resistant recurrent endometrial cancer having lesion measured by CT or MRI ECOG PS 0 or 1

Exclusion criteria

Exclusion criteria: Obvious infection, serous complication (heart disease, intestinal pneumonia, bleeding) edema greater than grade 2 neuropathy greater that\n grade 2 active other cancer symptomatic brain metastasis pleural effusion or ascites needed treatment pericardiac effusion

Design outcomes

Primary

Measure	Time frame
progression free survival	—

Secondary

Measure	Time frame
overall survival, response rate, toxicity	—

Countries

Japan

Contacts

Public ContactMasato Nishimura

Tokushima University hospital Obstetrics and Gynecology

nisimura@clin.med.tokushima-u.ac.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026